ClinicalTrials.gg

Program

HRS-6209

A development code. Also written as “HRS-6209 in Combination with HRS-1358”, “HRS-6209 + Letrozole” and “HRS-6209 in Combination with Fulvestrant”.

In Jiangsu HengRui Medicine's pipeline, CDK4. Its studies are mostly in Breast Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Oct 14, 20267 company-led studies, 7 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine77 open or runningphase 3since Oct 14, 2026Feb 23, 2023Dec 2026phase 2 · NCT06974929
  • Named in Jiangsu HengRui Medicine’s own pipeline as HRS-6209, phase 2, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 23, 2023First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05781048 · 56 enrolled · China
  2. Aug 1, 2024Phase 2 study in Breast NeoplasmsNCT06555068 · 528 planned · China
  3. Nov 6, 2024Phase 2 study in Breast NeoplasmsNCT06679036 · 300 planned · China
  4. May 8, 2025Phase 2 study in Breast NeoplasmsNCT06974929 · 80 planned · China
  5. Dec 28, 2025Phase 1 study in Breast NeoplasmsNCT07358377 · 15 planned · Australia
  6. May 20, 2026Phase 1 study in Breast NeoplasmsNCT07610148 · 21 enrolled · China
  7. Oct 14, 2026Phase 3 study in Breast NeoplasmsPhase 3 reachedNCT07894328 · 1,050 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Breast NeoplasmsNCT06974929
  2. Dec 30, 2026Primary completion: phase 1 study in Advanced Solid TumorsNCT05781048
  3. Apr 10, 2027Primary completion: phase 1 study in Breast NeoplasmsNCT07358377
  4. Dec 2027Primary completion: phase 2 study in Breast NeoplasmsNCT06555068

TargetBeta

“CDK4”the company's pipeline, read by Claude · source

Other programs on CDK4

ProgramCompanyFurthest phaseStudies
abemaciclibruleEli Lillyphase 449
palbociclibrulePfizerphase 436
trilaciclibrulePharmacosmosphase 414
atirmociclibPfizerphase 317
culmerciclibSino Biopharmaceuticalphase 311
CDK4 Inhibitor BGB-43395ruleBeOne Medicinesphase 34
narazaciclibrulehangzhou-hanx-biopharmaceuticals-ltdphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
TSL2109ruleChina Resources Pharmaceutical Groupphase 11

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07894328Breast Neoplasms · China3Not yet recruitingJul 30, 20311,050
NCT07610148Breast Neoplasms · China1Active, not recruitingSep 202621
NCT07358377Breast Neoplasms · Australia1RecruitingApr 10, 202715
NCT06974929Breast Neoplasms · China2RecruitingDec 202680
NCT06679036Breast Neoplasms · China2RecruitingOct 30, 2026300
NCT06555068Breast Neoplasms · China2RecruitingDec 2027528
NCT05781048Advanced Solid Tumors · China1Active, not recruitingDec 30, 202656

How it is read

Names in the registry

  • “HRS-6209 in Combination with HRS-1358”, 2 entries
  • “HRS-6209”, 2 entries
  • “HRS-6209 + Letrozole”, 1 entry
  • “HRS-6209 in Combination with Fulvestrant”, 1 entry
  • “HRS-6209 in Combination with Letrozole”, 1 entry

Codes read as this program: HRS6209.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.